Cite
HARVARD Citation
Rousseau, B. et al. (2019). Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. International journal of cancer. 144 (4), pp. 886-896. [Online].